The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Production of viral vectors requires a holistic view of the product, including its manufacturing process and its ultimate end use. Viral vectors must be free of contaminants, such as adventitious ...

Please provide your email address to receive an email when new articles are posted on . The word “innovation” connotes an element of time. An innovation is a leap forward, reaching a place that ...

As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...

Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

Effective and efficient manufacturing operations require close integration between long-run planning and short-run production scheduling. A testament to this is the decades-old field of research and ...